News Conference News ESC 2025 AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC Todd Neale September 01, 2025
News Conference News ESC 2024 Streamlined European AF Guidelines Emphasize ‘Whole’ Patient Todd Neale September 06, 2024
News Conference News ESC 2024 SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients Michael O'Riordan September 02, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
Presentation ESC 2024 Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes Presenter: Muthiah Vaduganathan September 01, 2024
News Conference News ESC 2024 Polypills Show Promise in Diverse Hypertensive Patient Groups L.A. McKeown August 31, 2024
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News ESC 2023 Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST Michael O'Riordan August 27, 2023
News Conference News ESC 2023 Routine ECMO in AMICS Patients Not Protective: ECLS-SHOCK Caitlin E. Cox August 26, 2023
News Conference News ESC 2023 STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function Shelley Wood August 25, 2023
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ESC 2021 PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer Michael O'Riordan August 30, 2021
News Conference News ESC 2021 LOOP and STROKESTOP: Impact of AF Screening May Hinge on Arrhythmia Burden Todd Neale August 29, 2021
News Conference News ESC 2021 New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT Shelley Wood August 28, 2021
News Conference News ESC 2021 Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD Michael O'Riordan August 28, 2021
News Conference News ESC 2020 Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients Shelley Wood September 04, 2020